

JILL T. JOHNSON, PHARM.D., BCPS

December 2022

Work Address:

University of Arkansas for Medical Sciences (UAMS)
College of Pharmacy, #522-4
4301 W. Markham Street
Little Rock, Arkansas 72205

Phone: 501-686-7919

Email: johnsonjillt@uams.edu

EDUCATION AND TRAINING

Doctor of Pharmacy Degree: May 1993

UAMS College of Pharmacy, Little Rock, Arkansas

ASHP-Accredited Residency Training: July 1993 to June 1994

Pharmacy Practice Residency, Veterans Affairs Medical Center, Little Rock, Arkansas

Pre-Pharmacy Education: August 1986 to May 1989

University of Arkansas, Fayetteville, Arkansas

PROFESSIONAL BOARD CERTIFICATION

NABP Pharmacist Licensure: Arkansas, since 1993

Board Certification in Pharmacotherapy Specialty (BCPS), 1997-2025

Immunizations Administration Certification, since 2020

Arkansas Collaborative Practice Certification

CURRENT PROFESSIONAL EXPERIENCE

July 2015-Present	Professor with Tenure, Department of Pharmacy Practice, UAMS, Little Rock, AR
July 1994 - Present	Interdisciplinary Team Member, General Medicine Service-Team 3A, University Hospital, UAMS, Little Rock, AR
	Vancomycin, Aminoglycoside, Warfarin, & TPN Monitoring Service
May 2016-Present	Committee Member, Institute for Clinical and Economic Review (ICER) Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC)
January 2004 - Present	Clinical Consultant, Arkansas State Employees/Public School Employees, Employee Benefits Division, Formulary Management for Prescription Drug Program
July 2004 - Present	Committee Member, University of Arkansas Systems Pharmacy Advisory Committee
January 2017 – Present	Clinical Pharmacy Consulting, Jill Johnson Consulting LLC, Established January 2017
January 2007 - Present	Board Member, AR Medicaid Drug Utilization Review Board (DUR Board)
June 1999 - Present	Voting Member, UAMS Hospital Pharmacy & Therapeutics Committee, Formulary Management
August 2005 - Present	Expert Witness Cases:
	March 2022, Diuretic use in Acute Kidney Failure death, Terry Polich, Lawson & Cates, Madison, Wisconsin
	August 2017-present, Polysubstance case, Woehrer Law Firm, Madison, Wisconsin
	April 2017, Methotrexate case, Trammell Piazza Law Firm, Little Rock, AR
	August 2015, Polysubstance case, Clifford & Raihala, Madison, Wisconsin
	March 2014, Opiate case, Calderhead, Lockemeyer & Peschke Law Office, Milford, Ohio

March 2014, Pharmacy Dispensing case, Rodey Law, Albuquerque, New Mexico
January 2008-2010, Clopidogrel & Aspirin case, Little Rock, AR
April 2007, Case 1:06-cv-02157-RWR, a class action complaint, Partners of Garwin
Gerstein & Fisher LLP, Plaintiff Louisiana Wholesale Drug Co., v. AstraZeneca
Pharmaceuticals
August 2005-June 2006, PPI case, Wilkes and McHugh Law Firm, Little Rock, AR

CURRENT TEACHING

1994-Present	<u>PhPr 6714 Clerkship in General Internal Medicine</u> Preceptor, Responsibilities: Rounding with Multidisciplinary General Internal Medicine Team, 2-fourth year pharmacy students per month, 5 months per year
2011-Present	<u>PhPr 7303 Evidence-Based Medicine, Biostatistics, Pharmacoeconomics</u> <u>Medical Literature Critical Appraisal</u> Course Coordinator & Lecturer (Fall 2008-Present) Lectures: Introduction to Evidence-based Medicine, EBM Framework/Asking Clinical Questions, Validity of Clinical Trials: Populations, External validity, Exclusion/Inclusion, Study Design: Controlled Trials, Randomization, Allocation Concealment, Blinding, Loss to Follow-up, Trial Results: Analysis by Intention to Treat vs Per Protocol Analysis, Factoring in Baseline Characteristics, Composite endpoints, Flawed Assumptions, Run-ins, Calculating Relative Risks, Number Needed to Treat/Harm; Interpreting Hazard Ratios, Odds Ratios, and 95% Confidence Intervals, Levels of Evidence, Statistical vs Clinical Significance, Practice Guidelines
2016-Present	<u>Special Problems Elective in EBM</u> Third-year Pharm.D. Students each semester
2019-Present	<u>PhPr 7306 Pharmacy Management</u> Third-year Pharm.D. Students Managed Care; Pharmaceutical Promotions
2010-Present	<u>PhPr 7103 Career Orientation</u> First-year Pharm.D. Students
1995- Present	<u>PhSc 7205 Clinical Pharmacokinetics</u> Heparin, Low Molecular Weight Heparins, DOACs, and Warfarin
2018-2022	<u>PhPr 7304 Therapeutics III</u> Multiple Sclerosis Drugs
2020	<u>PhPr 7203 Therapeutics I</u> Calcium, Phosphate, Acute Kidney Injury, Dialysis
2011-2019	<u>Residency Program Director</u> PGY1 Managed Care Residency, UAMS COP, graduated 6 residents

PEER-REVIEWED PUBLICATIONS

Book contributions, Invited Content:

1. **Johnson JT.** Evaluating Clinical Literature: An Overview. In: Aparasu RR, Bentley JP, eds. *Principles of Research Design and Drug Literature Evaluation*. 2nd Ed. NY, NY: McGraw Hill; 9/2019: Online Access Pharmacy, Chapter 17. <https://accesspharmacy.mhmedical.com/book.aspx?bookid=2733>
2. **Johnson JT.** Evaluating Clinical Literature: An Overview. In: Aparasu RR, Bentley JP, eds. *Principles of Research*

Design and Drug Literature Evaluation. 1st Ed. Burlington, MA: Jones & Bartlett Learning; 2014: 274-288.

3. Johnson JT. Clinical Scenario and Clinical Significance: Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission. Glennon RA, Dukat M. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Seventh Ed*. Philadelphia: Lippincott Williams & Wilkins; 2013: 366, 367, 392-3.

4. Johnson JT. Clinical Scenario and Clinical Significance: Central Analgesics. Williams DA, Roche VF, Roche EB. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Seventh Ed*. Philadelphia: Lippincott Williams & Wilkins; 2013: 659, 694.

5. Johnson JT. Clinical Scenario and Clinical Significance: Nonsteroidal Anti-Inflammatory Drugs. Borne R, Levi M, Wilson N. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Seventh Ed*. Philadelphia: Lippincott Williams & Wilkins; 2013: 987, 990, 1040-41.

6. Johnson JT. Clinical Scenario and Clinical Significance: Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission. Glennon RA, Dukat M. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Sixth Ed*. Philadelphia: Lippincott Williams & Wilkins; 2008: 418.

7. Johnson JT. Clinical Scenario and Clinical Significance: Opioid Analgesics. Fries DS. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Sixth Ed*. Philadelphia: Lippincott Williams & Wilkins; 2008: 652.

8. Johnson JT. Clinical Scenario and Clinical Significance: Nonsteroidal Anti-Inflammatory Drugs. Borne R, Levi M, Wilson N. In: Lemke TL, Williams DA, eds. *Foye's Principles of Medicinal Chemistry Sixth Ed*. Philadelphia: Lippincott Williams & Wilkins; 2008: 954.

Journal articles:

1. **Johnson J**, DeYoung O, Keisner S. Covering pitolisant instead of oxybate salts for cataplexy. *American Journal of Managed Care*. Submitted.

2. King J, McAdam-Marx C, McCaleb R, Davis D, Bemberg GB, **Johnson JT**. "Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan." *Journal of managed care & specialty pharmacy* 25.6 (2019): 646-651.

3. McCaleb, Rachael V., and **Jill T. Johnson**. "Severe, prolonged, denosumab-induced hypocalcemia with recovery after 111 days of high dose calcium supplementation: a case report." *AACE Clinical Case Reports* (2019).

<https://doi.org/10.4158/ACCR-2018-0295>

4. McAdam-Marx C, Li C, Hu B, Hight K, **Johnson J**. Trends in insulin costs and adherence in commercially insured patients with diabetes: 2007-2014. *J Manag Care Pharm*. 2018. (Submitted, voluntarily unsubmitted)

5. Shewale AR, **Johnson JT**, Li C, Nelsen D, Martin BC. Net clinical benefits of guidelines and decision tool recommendations for oral anticoagulant use among patients with atrial fibrillation. *J Stroke Cerebrovascular Dis*. 2015;24(12).

6. Shewale A, **Johnson J**, Li C, Nelsen D, Martin B. Variation in anticoagulant recommendations by the guidelines and decision tools among patients with atrial fibrillation. *Healthcare*. 2015;3(1):130-145.

7. Dayer LE, Hutchins LF, **Johnson JT**. Treatment of metastatic melanoma with pazopanib: a report of five patient cases. *Journal of Oncology Pharmacy Practice*. 2014. Online first:

<http://opp.sagepub.com/content/early/2014/02/27/1078155214524084>

8. Kaye CJ, Neill KK, Davis D, **Johnson JT**. Statin Cost and Utilization Outcomes after Implementation of Reference-based Pricing. *Am J Pharm Benefits*. 2013;5(1):e8-e14.

9. Neill KK, **Johnson JT**. An Advanced Pharmacy Practice Experience in Application of Evidence-based Policy. *American Journal of Pharmaceutical Education*. 2012;76(7) article 133.

10. **Johnson JT**, Neill, KK, Davis D. Five-Year Examination of Utilization and Drug Cost Outcomes Associated with Benefit Design Changes Including Reference Pricing for Proton Pump Inhibitors in a State Employee Health Plan. *J Manag Care Pharm*. 2011;17(3):200-12. April 2011. *nominated for the JMCP Award for Excellence, 2011.

11. Vanderbush RE, **Johnson JT**, Hutchison LC, West DS. Use of an Audience Response System in Continuing Education. 2006. *AJPE*;70(3), Abstract 65.

12. West DS, **Johnson JT**, Hong SH. A 30-month evaluation of the effects on the cost and utilization of proton

- pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. *J Manag Care Pharm.* 2006;12(1):25-32. *Nominated for the JMCP Award for Excellence. 2006.
13. **Johnson JT**, West DS. Using an Evidence-based Medicine Approach to Reduce costs for Proton-Pump Inhibitors in a State Employee Health Plan. *Drug Benefit Trends.* 2005;17(9):393-401.
14. Harris BN, West DS, **Johnson J**, Hong SH, Stowe C. Effects on the Cost and Utilization of Proton Pump Inhibitors from Adding OTC Omeprazole to Drug Benefit Coverage in a State Employee Health Plan. *J Manag Care Pharm.* 2004;10(5):449-550. *Nominated for Best Paper in JMCP 2004
15. **Johnson JT**, Stowe CD, Savidge MA, Gardner SF. Enhancing the Quantity and Quality of Student Comments on Teaching Assessment Tools. *Journal of Pharmacy Teaching.* 2004;11(1):41-56.
16. **Johnson JT**. Venous Thromboembolism Prophylaxis in the Medically Ill. *ARDONA Report.* 2003;4(1):3-4.
17. Granberry MC, **Johnson JT**, Myatt S, et al. Comparison of Evidence-Based Medicine Knowledge between Physician Faculty, Physician Residents and Pharmaceutical Industry Representatives. Abstract 11/02.
18. **Johnson JT**, Granberry MC, Thomas AR. Anticoagulation Management in Mechanical Heart Valve Patients who Undergo Dental Procedures. *J AR Med Society.* 2000;97(4):128-31.
19. Schneider EF, Gardner S, **Johnson JT**. Development of a Practical Examination Utilizing Standardized participants for Disease State Management Credentialing. *AmJPhEd.* 2000;64:173-75.
20. **Johnson JT**, Dunn EB, Wolfe JJ. Two antiretroviral drugs likely to be confused. *Am J Health-Syst Pharm.* 1998;55:1728.
21. Granberry MC, **Johnson JT**, Stafford AD, Carthan N. Implementation and evaluation of patient case-based discussion of optimal therapy derived from landmark studies and consensus statements. *AJPE.* 1998;62:110s.
22. DFCM-Pharmacy Group: Coulter L, Grady A, Granberry M, Geurian K, **Johnson J**, Marsh C, McCafferty R, Myatt SM, Schneider E. Case-based lecture versus standard lecture style. *AJPE.*

PRESENTATIONS (since year 2000)

INTERNATIONAL

- Poster Presentation: Shewale AR, Nelsen DA, **Johnson JT**, Li C, Martin B. Comparison of the guidelines and decision tool recommendations for oral anticoagulant use among patients with atrial fibrillation. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.
- Poster Presentation: Shewale AR, Nelsen DA, **Johnson JT**, Li C, Martin B. Comparison of decision support tools and guidelines used to guide anticoagulation therapy for patients with nonvalvular atrial fibrillation. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.
- Poster Presentation: Potukuchi PK, **Johnson JT**, Martin B, Hutchison LC, Bursac Z, Said Q. Treatment patterns of urinary incontinence in the presence of comorbidities. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.
- Poster Presentation: Potukuchi PK, **Johnson JT**, Martin B, Hutchison LC, Bursac Z, Said Q. Impact of arthritis and other comorbidities on incidence of urinary incontinence: a case control study. University of Arkansas for Medical Sciences, AR, USA. Accepted to ISPOR 19th Annual International Meeting. May 31 - June 4, 2014, at Palais des Congrès de Montréal, Montreal, QC, Canada.

NATIONAL

- Poster Presentation: **Johnson J**, Peng C, Dare R, Painter J, Maples H, Thomas J, Teeter B, Shoptaw E, Golden

W. Antibiotic Prescribing Changes in Adults During COVID-19 in Outpatient Patient-Centered Medical Homes (PCMH) in Arkansas. 2022. Presented at IDWeek 2022, Washington DC.

- Poster Presentation: Byrd K, Bailey B, **Johnson J**, DeYoung O, Hutchison L. Development and Implementation of a PGY2 Population Health Management and Data Analytics Pharmacy Residency Program. 2022. Presented at ASHP Midyear.
- Poster Presentation: Thomas J, Peng C, **Johnson J**, Maples H, Teeter B, Painter J, Dare R, Shoptaw E, Golden W. Impact of COVID on Antibiotic Prescribing Patterns in a Medicaid Population. 2022 ACCP Abstract #59634. Virtual Poster Presentation.
- Poster Presentation: Maples H, Peng C, Painter J, Dare R, **Johnson J**, Thomas J, Shoptaw E, Golden W. The Impact of Covid-19 on Pediatric Antimicrobial Prescribing in Primary Care Medical Homes in Arkansas. 2022. Pediatric Antimicrobial Stewardship Annual Meeting, St.Louis, MO.
- Poster Presentation: McAdam-Marx C, Li C, **Johnson J**. Trends in insulin cost share and utilization in commercially insured patients with diabetes: 2007-2014. AMCP Nexus Meeting, Orlando, FL, 10/2018.
- Poster Presentation: King J, McAdam-Marx C, Davis D, Bemberg GB, **Johnson JT**. Cost and utilization outcomes after exclusion of dipeptidyl peptidase-4 (DPP-4) inhibitors in a self-funded managed care plan. ACCP Virtual Poster Presentation. 2017.
- Poster Presentation: Mullings A, **Johnson JT**. Cost and Utilization Outcomes of Antivirals Used in the Treatment of Herpes Labialis After Exclusion of Topical Antivirals in a Self-Funded Managed Care Plan. AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA, April 20, 2016.
- Poster Presentation: Shewale AR, Nelsen DA, **Johnson JT**, Li C, Martin BC. Net clinical benefit of the 2014 AHA/ACC/HRS Guideline used to guide anticoagulation therapy for patients with nonvalvular atrial fibrillation. Southern Pharmacy Administration Conference (SpAC) Oklahoma City, OK, June 20-22, 2014.
- Poster Presentation: Dayer LE, Merrell KS, **Johnson JT**, Hutchins LF. Treatment of metastatic melanoma with pazopanib: a report of 5 patient cases. Presented at American Society of Health-Systems Pharmacists (ASHP) Midyear Clinical Meeting, Orlando, FL, December 8-12, 2013. (Poster #1-039)
- Poster Presentation: Kaye C, Davis DA, Neill KK, **Johnson J**. Statin Cost & Utilization Outcomes After Implementation of Reference-based Pricing. Presented at the 24th Annual Academy of Managed Care Pharmacy Meeting, San Francisco, CA. April 2012.
- Poster Presentation: Neill K, Warmack S, **Johnson J**, Gubbins P, Schneider E, Carle M. Implementation of a Faculty Item Review Process for Examination Content in the Therapeutics Coursework. Presented at the Annual Meeting of the American Association of Colleges of Pharmacy, Seattle, WA. July 2010; AJPE 2010;74(5) Article 96.
- National Webcast for Pharmacy Benefit Managers Institute. **Johnson JT** and Dickerson S. Arkansas State Employee Benefits Division. Prilosec OTC Program. November 8, 2006.
- Poster Presentation: Neill KK, **Johnson JT**, Gubbins PO. An Experience in Evidence-Based Policy Application (School Poster). 2005 American Association of Colleges of Pharmacy Annual Meeting and Seminars. Cincinnati, Ohio (July 2005);AJPE 2005;69(3) Article 60.
- **Johnson JT**. Aligning Payer, Pharmacy, and Beneficiary Interests, Pharmacy Benefit Management Institute Annual Conference, Scottsdale, AZ, March 30, 2005.
- Poster Presentation: Granberry MC, **Johnson JT**, Myatt S, McAfferty R, Sabbe J, Warmack S, Smith ES. Comparison of evidence-based medicine knowledge among physician faculty physician residents and pharmaceutical industry representatives. American College of Clinical Pharmacy, Palm Springs, CA, April 28, 2003.

STATE

- Desai V, **Johnson J**. An Evidence-based decision algorithm for drug coverage of IBS-C in adults. 2022. Presented at AAHP, Little Rock.

- McAdam-Marx C, Li C, **Johnson J**. Trends in insulin costs and utilization in commercially insured patients with diabetes: 2007-2014. Women in Research Poster Showcase. UAMS, 11/2019.
- Sanson S, **Johnson JT**. Development of evidence-based prior authorization criteria for onasemnogene abeparvovec-xioi (Zolgensma) as a medical benefit. Poster presented at AR Association of Health Systems Pharmacy (AAHP) Fall Seminar, Little Rock. 10/2019.
- **Johnson JT**. Arkansas Pharmacists Association Annual Meeting. New Drugs Presentation. 6/7/2018. Rogers, AR.
- McPhee AL, **Johnson JT**. Plaque Psoriasis and Psoriatic Arthritis: Formulation of Evidence-based Prior Authorization Criteria. Poster presented at AR Association of Health Systems Pharmacy (AAHP) Fall Seminar, Little Rock. 10/2018.
- Walsh T, King J, **Johnson JT**. Cyclin Dependent Kinase Inhibitors for Advanced Hormone Receptor Positive, HER2-negative Breast Cancer. Presented at AAHP Fall Seminar, Little Rock. 10/2018.
- Quattlebaum SH, **Johnson JT**. Development of an Evidence-Based Prior Authorization Pathway for Ibalizumab (Trogarzo®). Poster at AAHP Fall Seminar, Little Rock. 10/2018. ****Received Honorable Mention****
- McAdam-Marx C, Li C, **Johnson JT**. Trends in Insulin Cost Share and Utilization in Commercially Insured Patients with Diabetes: 2007-2014. Poster presented at 2018 AMCP Nexus, Orlando, FL.
- Bemberg GB, **Johnson JT**. Accessibility of Information Concerning the Ramifications of Drug Coupons. Poster presented at AAHP Fall Seminar, Little Rock. 10/2014.
- Dayer LE, Merrell KS, **Johnson JT**, Hutchins LF. Treatment of metastatic melanoma with pazopanib: a report of 5 patient cases. Presented at AAHP Fall Seminar, Little Rock, AR, 10/2013.
- Brazeal J, **Johnson JT**, Neill KK. Development of an Evidence-based Prior Authorization Pathway for Colony-Stimulating Factors. Presented at AAHP Fall Seminar, Hot Springs, AR, 10/2012.
- **Johnson JT**. “Roflumilast”. AR Medicaid Drug Utilization Review Board. Oct. 19, 2011.
- **Johnson JT**. “Newer Diabetes Drugs”. Arkansas State Employees Drug Utilization & Evaluation Committee. 2/8/2011.
- Neill KK, Fielder B, **Johnson JT**. Implementation of a Reference Pricing Strategy for Proton Pump Inhibitors in a State Employees Prescription Drug Plan (Poster). Presented at AAHP Fall Seminar, Little Rock. 10/2009.
- **Johnson JT**. Methadone: Do’s, Don’ts, and Dosing. COP CE Program-1hour, Little Rock, AR, 10/18/2009. ACPE Program No. 004-000-09-037-L01-P.
- Neill KK, Fielder B, **Johnson JT**. Six Month Follow-Up for Implementation of Formulary Revisions for Atorvastatin 80 mg Prescriptions (Poster). Presented at AAHP Fall Seminar, Tunica, MS. 10/10/2008. *****AAHP Fall Seminar Best Poster Award*****
- Neill KK, Fielder B, **Johnson JT**. The Impact of Implementation of Prior Authorization Criteria for omalizumab (Xolair®) in a State Employees Prescription Drug Plan (Poster). Presented at AAHP Fall Seminar, Tunica, MS. 10/10/2008.
- **Johnson JT** Area Health Education Center (AHEC) Pine Bluff, “Evidence-based Medicine & Interpreting Therapy Articles”, Medical Resident and Staff Noon Conference, 2/5/2008.
- **Johnson JT**. “No Free Lunch, Just Say ‘No’”, COP CE Program-1hour, Alumni Weekend, Little Rock, AR, 10/2006. ACPE Program No. 004-000-06-039L04.
- **Johnson JT**. Antithrombotic Guidelines Update from the American College of Chest Physicians, UAMS COP CE Program-1hour, Destin, FL, 8/2005.
- **Johnson JT**. Evidence-based Medicine, UAMS COP CE Program 2-hours, Destin, FL, 8/2005.
- **Johnson JT**. Anticoagulation: New and Old, Arkansas Association of Hospital Pharmacists, Annual Meeting, 6/10/2004.

LOCAL (“COP” is College of Pharmacy.)

-
- **Johnson JT.** Managed Care Pharmacy. Noon workshop for implementing a student chapter of the Academy of Managed Care Pharmacy. 10/2019.
 - **Johnson JT.** Managed Care Pharmacy-What is it? P1 Career Orientation. 2019, 2020.
 - **Johnson JT.** Working with Clerkship Students. Mentoring New COP Faculty. 2018.
 - GB Bemberg, **Johnson JT.** Pharmacy Benefit Experience. Stephens Insurance. Little Rock, AR, 2/21/18.
 - **Johnson JT.** Anticoagulants-The Old and the New. 12/4/11. ACPE No. 0004-0000-11-061-L01-P.
 - **Johnson JT.** UAMS COP Residency Teaching Certificate Program, “Evidence-based Medicine”, 7/23/2008.
 - **Johnson JT.** UAMS Family Medical Center, Noon Conference, “EBM”, 7/9/2008.
 - **Johnson JT.** UAMS COP Seminar, “There’s No Free Lunch: Promoting Healthy Skepticism”, 9/7/2007.
 - **Johnson JT.** PBM, PPO, and EBM: Alphabet Soup in Today’s Pharmacy Environment, 5/23/2005. ACPE No.004-000-05-031-L01.
 - **Johnson JT.** PPI’s: what the Hospital pharmacist Needs to Know, UAMS COP CE Program, 10/29/2004, ACPE No.004-000-04-032-L01.
 - **Johnson JT.** Anticoagulant Pharmacology, Grand Rounds for Cardiology and CV Surgery, 11/2003.
 - **Johnson JT.** Update on Post-Menopausal Osteoporosis, UAMS Learn @ Noon Conference, 11/5/2002, and for Arkansas Pharmacists CE, 11/10/2002. ACPE No. 004-000-02-015-L01
 - **Johnson JT.** Issues Related to DVT Prophylaxis in Long-Term Care Patients: Opportunities to Prevent VTE, for the Donald W. Reynolds Center on Aging, sponsored by the UAMS COP and the Arkansas Pharmacists’ Association Academy of Consultant Pharmacists, 10/20/02. ACPE No. 004-000-02-012-L-01.
 - **Johnson JT.** Issues Related to DVT Prophylaxis in Long-Term Care Patients: Missed Opportunities to Prevent VTE, Local Consultant Panel Sponsored by Aventis Pharmaceuticals, 9/9/2002.
 - **Johnson JT** Increased Student Participation in the Evaluation of Faculty in a Team-taught Course, UAMS Teaching Scholars, 2/20/2001.
 - **Johnson JT** Gastrointestinal Drugs, UAMS Graduate Nursing Course, 3 hours, Fall & Spring 1996-2001.
 - **Johnson JT** Polycystic Ovary Syndrome, ACPE No. 177-000-00-.004-L01, CE for Pharmacists, 6/8/2000, Arkansas Pharmacists Association.

EDITORIAL REVIEW

-
- **2020-present** American Journal of Managed Care, Reviewer
 - 2016 Pharmacotherapy Preparatory Review and Recertification Course, Study Designs chapter, Dec 2015.
 - Textbook Chapter 10: Venous Thromboembolism. Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, eds. Pharmacotherapy Principles & Practice, 3rd edition, 2013.
 - Textbook Chapter: Ch. 7 Venous Thromboembolism. Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, eds. Pharmacotherapy Principles & Practice, 2nd edition, 2010.
 - ASHP PharmPrep Reviewer. Anemia Chapter. September 2010.
 - Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Current Medical Research & Opinion. Dec 2009.
 - 2009 PSAP Reviewer for Anemias in the Chronic Illnesses Chapter.
 - Textbook Chapter: Ch. 7 Venous Thromboembolism. Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, eds. Pharmacotherapy Principles & Practice, 1st edition, 2008.

RESEARCH INVOLVEMENT

- Co-investigator; Evaluation of the Arkansas Medicaid Antibiotic Prescribing Program. PEW and Arkansas Department of Health. PI: William Golden, \$140,000 subcontract 7/1/21-6/30/22.
- Co-Investigator; Pilot Evaluation of an Audience Response System in a Pharmacist Continuing Education Meeting. Vanderbush R, **Johnson JT**, Hutchison L, West DS., 8/05.
- Study Coordinator and Sub-Investigator; A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization (EXCLAIM), \$113,500 from Aventis, UAMS, Little Rock, Arkansas, Rob Lavender, M.D., **Jill Johnson, Pharm.D.** 8/05.
- Study Coordinator; Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H376/95 Compared with Dose-Adjusted Warfarin (Coumadin®) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V), \$46,000 from Astra-Zeneca. UAMS, Little Rock, Arkansas, Eugene Smith, M.D., **Jill Johnson, Pharm.D.**
- A Retrospective Chart Review to compare anticoagulated atrial fibrillation patients in a private clinic vs. a university clinic's anticoagulation monitoring service. UAMS, Little Rock, Arkansas
- Improvement of Students' Assessment of Faculty in a Team-Taught Course, Teaching Scholars Formal Proposal. UAMS College of Pharmacy. Fall 1999-Spring 2000
- Study Coordinator; Challenge Study: A Multi-Center, Open-Label Study of Atorvastatin 10mg or 80mg or Simvastatin 20mg or 80mg in the Treatment of Patients with Hypercholesterolemia, \$69,000 from Parke-Davis. UAMS, Little Rock, Arkansas, 1998-1999
- Residency Project: An Open-Label Study of Fluvastatin in the Treatment of Patients with Hypercholesterolemia in Clinical Practice Settings, \$7200. Veterans Affairs Medical Center, Little Rock, Arkansas, 1993-1994

SERVICE

NATIONAL (current in BOLD)

- **Institute for Clinical and Economic Review Midwest Comparative Effectiveness Public Advisory Council (ICER Midwest CEPAC), 2016-2018, 2018-present**
- National Association of Boards of Pharmacy (NABP) Naplex Item Writing Committee Member, 2017
- National Association of Boards of Pharmacy (NABP) Disease State Management-Anticoagulation Review Committee, 1999-2005
- NABP Disease State Management-Anticoagulation Exam Item-writing Facilitator, 2002
- Board of Pharmaceutical Specialties Internal Medicine Item-writing Committee, 1999
- NABP Disease State Management-Anticoagulation Exam Item-writing Committee, 1998
- NABP Disease State Management-Anticoagulation Exam Passing Standard Committee, 1998

STATE/REGIONAL (current in BOLD)

- **Arkansas Medicaid Drug Utilization Review Board, Feb 2003 to Dec 2004, Jan 2007 to present**
- **Arkansas State Employees' Benefits Consultant, Jan 2004 to present**
- **Arkansas State Employees' Delivery Coordination Working Group, a subcommittee to the Drug Use and Evaluation Committee, 2013-present**
- Pharmacy Advisory Committee Member, (large insurer in AR and beyond), 2016-2018
- Arkansas State Medicaid Drug Review Committee for the Arkansas Medicaid Evidence-based Prescription Drug

- Program, Nov 2004-May 2005, June 2005-Nov 2005, May 2006-Nov 2006, Jan 2010-June 2016
- Pharmacy & Therapeutics Voting Member, (large insurer in AR and beyond), 2014
 - Arkansas Department of Health (ADH) Viral Hepatitis Epidemiologic Profile Stakeholder, April 2014
 - Arkansas State Employees' Benefits Division, Ad Hoc Member, RFP Proposal Evaluation Team for Pharmacy Benefits Audit, June 2007
 - Mid-South College of Clinical Pharmacy Pharmacotherapy Exam Scholarship Committee, 1998

UNIVERSITY (current in BOLD)

- **University Hospital Pharmacy and Therapeutics Committee, Voting Member, 1999 to present**
 - **Subcommittee on Targeted High Cost Drugs, 2021-present**
 - Subcommittee on Formulary Limits, 2010
 - Subcommittee on Statin Therapeutic Interchange 5/2006
- **University of Arkansas System Pharmacy Advisory Committee, 2004 to present**
 - RFP Team for PBM selection 2009
 - RFP Team for Pharmacy Consultant selection 2008
 - RFP Team for PBM selection 2006
- Faculty Life Cycle Committee, 2014
- Academic Services Advisory Committee, 2008-2010
- Teaching Scholar 1998-2001
- Ad Hoc Committee Member for the Expansion of the UAMS Anticoagulation Clinic, 1999

COLLEGE (current in BOLD)

- **Evidence-based Prescription Drug Program Pharmacy & Therapeutics Committee, Chair 2012-present**
- **Promotion and Tenure Committee Member: 2022-2023 (Alternate), 2019-2021, 2016-2018 (Chair 2017), 2014-2016 (Chair 2015, 2016), 2012-2014, 2010-2012, 2007-2008 Alternate, 2005-2007, 2002-2004**
- **Scholastic Standing Committee 2022-2024**
- **Chancellor's (Faculty) Appeal Board, 2022-present**
- Promotion & Tenure Ad Hoc Committee to Revise the P&T Document (Chair) 2017-2018, document approved
- Residency Review Committee, Member, Ad Hoc Committee in Pharmacy Practice, 2014-2016, 2016-2018
- Special Accommodations Committee, 2016
- Search Committee for Division Head, Pharmaceutical Evaluation & Policy (PEP), 2016
- MICU Candidate Search Committee, Chair 2014
- COP *ad hoc* Special Test Taking Accommodations Committee, 2007-2010
- Student-Faculty Affairs Committee, 2-year term: 2005-2007, 2007-2009
- Undergraduate Admissions Committee, 2-year term: 1997-2000, 2009
- Leadership Team, ACPE Standards for Self-Study Committee 2006-2007
- Scholastic Standing Committee, Chair, 2002-2003
- Faculty Assessment Committee, 1999
- Ad Hoc Committee Member for Non-tenure track Faculty 1998
- UAMS Student Awards Committee 1995, 1996
- Pharmacy Documentation Committee 1996